NCT03449381 2026-03-31This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)Boehringer IngelheimPhase 1 Completed266 enrolled
NCT03964233 2026-02-18A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)Boehringer IngelheimPhase 1 Completed119 enrolled